T Younis1, A Lee2, M E Coombes3, N Bouganim4, D Becker2, C Revil5, G S Jhuti5. 1. Division of Medical Oncology, Department of Medicine, Dalhousie University, Queen Elizabeth ii Health Sciences Centre, Halifax, NS. 2. Quadrant Health Economics Inc., Cambridge, ON. 3. Hoffmann-La Roche Limited, Mississauga, ON. 4. Cedars Cancer Centre, McGill University Health Centre, Montreal, QC. 5. F. Hoffmann-La Roche Limited, Basel, Switzerland.
Abstract
Background: In the katherine trial, adjuvant trastuzumab emtansine [T-DM1, Kadcyla (Genentech, South San Francisco, CA, U.S.A.)], compared with trastuzumab, significantly reduced the risk of recurrence or death by 50% (unstratified hazard ratio: 0.50; 95% confidence interval: 0.39 to 0.64; p < 0.0001) in patients with her2-positive early breast cancer (ebc) and residual invasive disease after neoadjuvant systemic treatment. A cost-utility evaluation, with probabilistic analyses, was conducted to examine the incremental cost per quality-adjusted life-year (qaly) gained associated with T-DM1 relative to trastuzumab, given the higher per-cycle cost of T-DM1. Methods: A Markov model comprising a number of health states was used to examine clinical and economic outcomes over a lifetime horizon from the Canadian public payer perspective. Patients entered the model in the invasive disease-free survival (idfs) state, where they received either T-DM1 or trastuzumab. Transition probabilities between the health states were derived from the katherine trial, Canadian life tables, and published literature from other relevant clinical trials (emilia, cleopatra, and M77001). Resource use, costs, and utilities were derived from katherine, other clinical trials, published literature, provincial fee schedules, and clinical expert opinion. Sensitivity analyses were conducted for key assumptions and model parameters. Results: Compared with trastuzumab, adjuvant T-DM1 was associated with a cost savings of $8,300 per patient and a 2.16 incremental qaly gain; thus T-DM1 dominated trastuzumab. Scenario analyses yielded similar results, with T-DM1 dominating trastuzumab or producing highly favourable incremental cost-utility ratios of less than $10,000 per qaly. Conclusions: Adjuvant T-DM1 monotherapy is a cost-effective strategy compared with trastuzumab alone in the treatment of patients with her2-positive ebc and residual invasive disease after neoadjuvant systemic treatment. 2020 Multimed Inc.
Background: In the katherine trial, adjuvant trastuzumab emtansine [T-DM1, Kadcyla (Genentech, South San Francisco, CA, U.S.A.)], compared with trastuzumab, significantly reduced the risk of recurrence or death by 50% (unstratified hazard ratio: 0.50; 95% confidence interval: 0.39 to 0.64; p < 0.0001) in patients with her2-positive early breast cancer (ebc) and residual invasive disease after neoadjuvant systemic treatment. A cost-utility evaluation, with probabilistic analyses, was conducted to examine the incremental cost per quality-adjusted life-year (qaly) gained associated with T-DM1 relative to trastuzumab, given the higher per-cycle cost of T-DM1. Methods: A Markov model comprising a number of health states was used to examine clinical and economic outcomes over a lifetime horizon from the Canadian public payer perspective. Patients entered the model in the invasive disease-free survival (idfs) state, where they received either T-DM1 or trastuzumab. Transition probabilities between the health states were derived from the katherine trial, Canadian life tables, and published literature from other relevant clinical trials (emilia, cleopatra, and M77001). Resource use, costs, and utilities were derived from katherine, other clinical trials, published literature, provincial fee schedules, and clinical expert opinion. Sensitivity analyses were conducted for key assumptions and model parameters. Results: Compared with trastuzumab, adjuvant T-DM1 was associated with a cost savings of $8,300 per patient and a 2.16 incremental qaly gain; thus T-DM1 dominated trastuzumab. Scenario analyses yielded similar results, with T-DM1 dominating trastuzumab or producing highly favourable incremental cost-utility ratios of less than $10,000 per qaly. Conclusions: Adjuvant T-DM1 monotherapy is a cost-effective strategy compared with trastuzumab alone in the treatment of patients with her2-positive ebc and residual invasive disease after neoadjuvant systemic treatment. 2020 Multimed Inc.
Entities:
Keywords:
Early breast cancer; adjuvant her2-positive therapy; cost-utility analyses; economic evaluations; trastuzumab emtansine
Authors: Francesco Schettini; Giuseppe Buono; Cinzia Cardalesi; Isacco Desideri; Sabino De Placido; Lucia Del Mastro Journal: Cancer Treat Rev Date: 2016-04-01 Impact factor: 12.111
Authors: C L Attard; A N Pepper; S T Brown; M F Thompson; P-O Thuresson; S Yunger; S Dent; A H Paterson; G A Wells Journal: J Med Econ Date: 2014-11-10 Impact factor: 2.448
Authors: Andreas Schneeweiss; Stephen Chia; Tamas Hickish; Vernon Harvey; Alexandru Eniu; Maeve Waldron-Lynch; Jennifer Eng-Wong; Sarah Kirk; Javier Cortés Journal: Eur J Cancer Date: 2017-12-08 Impact factor: 9.162
Authors: Hugh Walker; Mark Anderson; Farah Farahati; Doris Howell; S Lawrence Librach; Amna Husain; Jonathan Sussman; Raymond Viola; Rinku Sutradhar; Lisa Barbera Journal: J Palliat Care Date: 2011 Impact factor: 2.250
Authors: Stephen Chia; Brian Norris; Caroline Speers; Maggie Cheang; Blake Gilks; Allen M Gown; David Huntsman; Ivo A Olivotto; Torsten O Nielsen; Karen Gelmon Journal: J Clin Oncol Date: 2008-11-10 Impact factor: 44.544
Authors: A G E M de Boer; J H A M Verbeek; E R Spelten; A L J Uitterhoeve; A C Ansink; T M de Reijke; M Kammeijer; M A G Sprangers; F J H van Dijk Journal: Br J Cancer Date: 2008-03-18 Impact factor: 7.640